Robert Jr Laforce
Chercheur universitaire clinicien
Axe Neurosciences
Publications
View all-
article Carrier-Auclair J, Lavoie M, Tastevin M, Laforce R
Efficacy of Acetylcholinesterase Inhibitors in the Logopenic Variant of Primary Progressive Aphasia
Dement Geriatr Cogn Disord 54 (1), 2025.
-
article Mulet-Perreault H, Landry M, Laforce RJ, Macoir J, Hudon C
Mini-SEA: Validity and Normative Data for the French-Quebec Population Aged 50 Years and Above
Arch Clin Neuropsychol 40 (3), 2025.
-
article Coleman KKL, Berry S, Cummings J, Hsiung GR, Laforce R, Huey E, Ducharme S, Tartaglia MC, Mendez MF, Onyike C, Domoto-Reilly K, Masellis M, Herrmann N, Porsteinsson A, Detry MA, Stewart C, Bosse AL, McGlothlin A, Dias B, Pandey S, Mayich M, Pasternak SH, Ruiz Garcia R, Restrepo-Martinez M, Feldman H, Boxer AL, Finger EC
Intranasal oxytocin for apathy in people with frontotemporal dementia (FOXY): a multicentre, randomised, double-blind, placebo-controlled, adaptive, crossover, phase 2a/2b super…
Lancet Neurol 24 (2), 2025.
Projects
- DIAN-TU : A Phase II Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multicenter Study of Potential Disease Modifying Therapies in Individuals at Risk for and with Dominantly Inherited Alzheimer’s Disease, from 2020-06-01 to 2026-05-31
- Genetic Frontotemporal Dementia Initiative (GENFI) in Canada: Combined Investigation of Clinical, MRI, Genomic, and Epigenomic Biomarkers, from 2021-04-01 to 2026-03-31
- Neurodevelopmental vs. Neurodegenerative: A study of neurodevelopmental consequences of FTD genetic mutations in at-risk youth, from 2022-04-01 to 2027-03-31
- Chaire de recherche sur les aphasies primaires progressives, from 2024-07-01 to 2029-06-30
- L'homocystéine, une molécule utile pour prédire le déclin cognitif dans la maladie de Parkinson et la démence à corps de Lewy, from 2024-06-25 to 2026-09-30
- Caractérisation en TEP-18FDG du substrat neuro-fonctionnel de la dépression résistante du sujet âgé, from 2025-06-02 to 2028-06-30
- Phase Two of the Canadian Consortium on Neurodegeneration in Aging, from 2019-04-01 to 2024-03-31
- Chaire de recherche sur les aphasies primaires progressives, from 2019-07-01 to 2024-06-30
- L'hyperhomocystéinémie:étude de son potentiel comme biomarqueur du déclin cognitif commun à la démence à corps de Lewy et à la maladie de parkinson pour améliorer le diagnostic et le traitement des patients, from 2024-01-23 to 2024-12-31
- A Phase III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multicenter Study of Potential Disease Modifying Therapies in Individuals at Risk for and with Dominantly Inherited Alzheimer’s Disease, from 2024-06-01 to 2025-05-31